Copyright ©The Author(s) 2022.
World J Gastrointest Endosc. May 16, 2022; 14(5): 267-290
Published online May 16, 2022. doi: 10.4253/wjge.v14.i5.267
Figure 1
Figure 1 Epidemiology of gastroenteropancreatic neuroendocrine neoplasms.
Figure 2
Figure 2 Epidemiology of pancreatic neuroendocrine neoplasms.
Figure 3
Figure 3 Computerized tomography scan of hyperenhancing pancreatic neuroendocrine tumor (white arrow).
Figure 4
Figure 4 Magnetic resonance imaging with T1 hypointense and T2 mildly hyperintense well-defined peri-pancreatic neuroendocrine tumor. A: T1 hypointense; B: T2 mildly hyperintense.
Figure 5
Figure 5 Gallium-68 DOTATATE positron emission tomography/computed tomography demonstrating avid lymph nodes.
Figure 6
Figure 6 Endoscopic ultrasound of pancreatic neuroendocrine tumor appearing well-defined and hypoechoic.
Figure 7
Figure 7 Endoscopic and endoscopic ultrasound views of type 1 small, superficial neuroendocrine lesions in gastric body. A and B: Endoscopic; C: Endoscopic ultrasound.
Figure 8
Figure 8 Endoscopic imaging of duodenal neuroendocrine tumors.
Figure 9
Figure 9 Treatment algorithm for pancreatic neuroendocrine tumors. NET: Neuroendocrine tumor; SSA: Somatostatin analogue; PRRT: Peptide receptor radionuclide therapy.